Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2012 Nov;22(11):1723-9.
doi: 10.1007/s11695-012-0719-8.

Equivalent weight loss with marked metabolic benefit observed in a matched cohort with and without type 2 diabetes 12 months following gastric bypass surgery

Kathleen Yip  1 , Leslie Heinberg, Victoria Giegerich, Philip R Schauer, Sangeeta R Kashyap
Affiliations
Comparative Study

Equivalent weight loss with marked metabolic benefit observed in a matched cohort with and without type 2 diabetes 12 months following gastric bypass surgery

Kathleen Yip et al. Obes Surg. 2012 Nov.

Abstract

Background: Bariatric surgery results in dramatic weight loss and improves metabolic syndrome and type 2 diabetes (T2DM). However, previous studies have noted that morbidly obese patients with T2DM experience less weight loss benefits than non-diabetic patients following bariatric surgery. We sought to determine longitudinal effects of laparoscopic Roux-en-Y gastric bypass (LRYGB) on percent excess body mass index (BMI) loss (%EBMIL) and clinical metabolic syndrome parameters in patients with T2DM compared with appropriately matched cohort without T2DM.

Methods: Retrospective cohort analysis of T2DM patients (n = 126) to non-T2DM patients (n = 126) matched on age (M = 48.1 ± 9.5), sex (81 % female), race (81 % Caucasian), and pre-surgical BMI (M = 49.3 ± 9.5). Lipids, glucose, hemoglobin A1c, blood pressure, co-morbidities of obesity, medications for co-morbidities, and T2DM medications were collected at baseline, 6 months and 12 months post-surgery. %EBMIL was collected at 1, 3, 6, 9, and 12 months post-surgery. One-way analyses of variance with effect sizes estimates were conducted to compare the two groups.

Results: As expected, T2DM subjects had significantly greater pre-surgical HbA1c, blood glucose, blood pressure, and lipid parameters at baseline vs. non-T2DM (all p values of<0.05). At 1, 3, 6, 9, and 12 months after LRYRB, both groups had similar reduction in %EBMIL (p > 0.10). At 6 months, there was a significant reduction in HbA1c, blood glucose, and lipid in the T2DM cohort compared with pre-surgical levels (p < 0.0001). At 12 months, these values were not different to that of the non-T2DM subjects (p > 0.10).

Conclusions: When matched on appropriate factors associated with weight loss outcomes, severely obese patients with T2DM have similar post-LRYGB weight loss outcomes in the first 12 months following surgery compared with non-T2DM patients. Furthermore, T2DM surgical patients achieved significant improvement in metabolic syndrome components.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: SRK and PRS disclose grant support from Ethicon Endo-surgery, Inc. PRS is also on the scientific advisory board of SurgiQuest, Barosense, and Surgical Excellence; acts as consultant for C.R. Bard, Ethicon Endo-surgery, Inc., Baxter Healthcare, Stryker, Cardinal Health, and W.L. Gore & Associates, Inc.; and acts in a fiduciary capacity to the MISS Surgery Symposium, Physician Review of Surgery and RemedyMD. LJH discloses grant support from Nutrisystems, Inc. The other authors (KY, VG) have nothing to disclose.

Figures

Figure 1
Figure 1
Comparisons of the T2DM and non-T2DM groups after LYRGB through (A) Percent excess BMI lost as a measure of weight loss, (B) glucose, in mg/dL, and (C) triglyceride (solid) and cholesterol (hashed) levels depicted on the y-axes. Values are listed as mean (±SD).
Figure 2
Figure 2
Percentage of T2DM patients meeting ADA guidelines, defined to be LDL cholesterol < 100, blood pressure 130/80, and HbA1c < 7.0%.
See this image and copyright information in PMC

References

    1. U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995;44:1249–58. - PubMed
    1. Cook MN, Girman CJ, Stein PP, et al. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care. 2005;28:995–1000. - PubMed
    1. Kahn SE, Haffner SM, Heise MA, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006;355:2427–43. - PubMed
    1. Koro CE, Bowlin SJ, Bourgeois N, et al. Glycemic control from 1988 to 2000 among U.S. adults diagnosed with type 2 diabetes: a preliminary report. Diabetes Care. 2004;27:17–20. - PubMed
    1. Pi-Sunyer X, Blackburn G, Brancati FL, et al. Reduction in weight and cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. Diabetes Care. 2007;30:1374–83. - PMC - PubMed

Publication types

MeSH terms